Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 4/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | FLT1 | P17948 | 4/20 | 0.42 |
| ▸ | FLT4 | P35916 | 4/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | PLK4 | O00444 | 3/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383307 | 0.88 | KDR (0.49) | FLT3MAP4K1KDRMAP2K7AURKA | |
| SCHEMBL3386700 | 0.86 | KDR (0.48) | FLT3MAP4K1KDRMAP2K7AURKA | |
| SCHEMBL3387473 | 0.84 | PAK1 (0.48) | KCNH2PAK1KDRAURKAGSK3B | |
| SCHEMBL3386670 | 0.83 | RAF1 (0.52) | FLT3KCNH2PAK1KDRAURKA | |
| SCHEMBL13336967 | 0.73 | KDR (0.61) | FLT3MAP4K1KDRAURKAROCK2 | |
| SCHEMBL3387051 | 0.73 | KDR (0.47) | PAK1KDRAURKAGSK3BAAK1 | |
| SCHEMBL3386722 | 0.71 | RAF1 (0.53) | FLT3KDRAURKAROCK2FLT1 | |
| SCHEMBL15942819 | 0.70 | HDAC3 (0.54) | FLT3MAP4K1DYRK1AGSK3BITK | |
| SCHEMBL3386648 | 0.70 | KDR (0.52) | FLT3PAK1KDRAURKAROCK2 | |
| SCHEMBL1330072 | 0.69 | KDR (0.75) | FLT3KDRMAP2K7AURKAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754209-B2 | Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-17 | — | — | US | claimed |
| US-20120130069-A1 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-05-24 | — | — | US | claimed |
| US-8754209-B2 | Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-17 | — | — | US | disclosed |
| US-8754209-B2 | Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-17 | — | — | US | disclosed |
| US-20120130069-A1 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-05-24 | — | — | US | disclosed |
| US-20120130069-A1 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-05-24 | — | — | US | disclosed |
| WO-2010064875-A2 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010064875-A2 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130069-A1 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | RAF1, RET, KDR | FLT3 59/4885MAP4K1 74/4885KCNH2 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.